BR112015003198A2 - formulação injetável de daptomicina melhorada. - Google Patents

formulação injetável de daptomicina melhorada.

Info

Publication number
BR112015003198A2
BR112015003198A2 BR112015003198A BR112015003198A BR112015003198A2 BR 112015003198 A2 BR112015003198 A2 BR 112015003198A2 BR 112015003198 A BR112015003198 A BR 112015003198A BR 112015003198 A BR112015003198 A BR 112015003198A BR 112015003198 A2 BR112015003198 A2 BR 112015003198A2
Authority
BR
Brazil
Prior art keywords
daptomycin
injectable formulation
improved injectable
improved
formulation
Prior art date
Application number
BR112015003198A
Other languages
English (en)
Portuguese (pt)
Inventor
Justin Babu
Srinivas Meda Sathyanarayan
Srinivas Chetlapalli Satya
Sarveswara Rao Mandavilli Srirama
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of BR112015003198A2 publication Critical patent/BR112015003198A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015003198A 2012-08-23 2013-08-22 formulação injetável de daptomicina melhorada. BR112015003198A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
BR112015003198A2 true BR112015003198A2 (pt) 2017-10-10

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003198A BR112015003198A2 (pt) 2012-08-23 2013-08-22 formulação injetável de daptomicina melhorada.

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE13837694T1 (de) 2012-09-11 2015-12-31 Hospira Australia Pty Ltd. Daptomycinformulierungen und Verwendungen davon
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
WO1997014705A1 (fr) * 1995-10-17 1997-04-24 Showa Denko K.K. Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
CA2611831C (en) * 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CA2772660A1 (en) * 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
BR112012012406B1 (pt) * 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
AU2011213557B2 (en) * 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
ES2655215T3 (es) 2018-02-19
DK2887953T3 (en) 2018-01-15
WO2014045296A2 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
AU2018204334A1 (en) 2018-07-05
AU2013319737B2 (en) 2018-08-02
EP3287138A1 (en) 2018-02-28
PT2887953T (pt) 2018-01-10
JP2015526463A (ja) 2015-09-10
CA2881121A1 (en) 2014-03-27
NO2887953T3 (enExample) 2018-03-10
EP2887953A4 (en) 2016-05-25
SI2887953T1 (en) 2018-02-28
EP2887953B1 (en) 2017-10-11
AU2013319737A1 (en) 2015-02-05
US20150216928A1 (en) 2015-08-06
EP2887953A2 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
PT3030262T (pt) Composição farmacêutica de associação
BR112015003227A2 (pt) processos de clicoconjugação e composições
DK2841054T3 (da) Injicerbart præparat
CO7061086A2 (es) Combinaciones de compuestos activos
FR2997014B1 (fr) Composition sterile dermo-injectable
EP2925298A4 (en) STABILIZED VANCOMYCIN FORMULATIONS
BR112014032798A2 (pt) composição
BR112014029176A2 (pt) formulações injetáveis de aprepitante
EP2925325A4 (en) STABILIZED FORMULATION OF PEMETREXED
DK2868318T3 (da) Injicerbar formulering
ME03413B (me) Kompozicije које sadrže peg i askorbat
PT2825039T (pt) Formulação de ibuprofeno injetável
EP2934121A4 (en) IMPROVED ANTIMICROBIAL COMPOSITIONS
FR2993777B1 (fr) Composition photo-protectrice
EP2925338A4 (en) LYOPHILIZED FORMULATION OF TAT-NR2B9C
DK2897594T3 (da) Farmaceutisk sammensætning
EP2857482A4 (en) Perfume composition
BR112014031998A2 (pt) conjunto de injeção
CL2015003366A1 (es) Composiciones de aceites estructuradas.
EP2881431A4 (en) Viscous composition
EP2905011A4 (en) PERFUME COMPOSITION
BR112014032712A2 (pt) composição
BR112015003198A2 (pt) formulação injetável de daptomicina melhorada.
BR112014028443A2 (pt) composição estéril.
CL2015000923A1 (es) Composiciones cancerigenas inyectables

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements